Facelift Patients Receiving Intraoperative Administration of a Self-assembling Hemostat Agent Experienced Minimal Bruising and No Acute Hematomas: A Pilot Study
J Few - Aesthetic Surgery Journal Open Forum, 2022 - academic.oup.com
J Few
Aesthetic Surgery Journal Open Forum, 2022•academic.oup.comBackground Hematomas are consistently cited as the most common complication of facelift
surgery, with reported incidence rates ranging from 1% to 9% despite preventative
measures. A self-assembling RADA16 peptide solution (PuraSinus, 3-D Matrix, Newton, MA)
designed to aid in wound healing, adhesion prevention, and bleeding control has
demonstrated hemostatic control of intra-and postoperative bleeding associated with various
surgical procedures, including nasal and sinus surgery. Objectives To report surgical …
surgery, with reported incidence rates ranging from 1% to 9% despite preventative
measures. A self-assembling RADA16 peptide solution (PuraSinus, 3-D Matrix, Newton, MA)
designed to aid in wound healing, adhesion prevention, and bleeding control has
demonstrated hemostatic control of intra-and postoperative bleeding associated with various
surgical procedures, including nasal and sinus surgery. Objectives To report surgical …
Background
Hematomas are consistently cited as the most common complication of facelift surgery, with reported incidence rates ranging from 1% to 9% despite preventative measures. A self-assembling RADA16 peptide solution (PuraSinus, 3-D Matrix, Newton, MA) designed to aid in wound healing, adhesion prevention, and bleeding control has demonstrated hemostatic control of intra- and postoperative bleeding associated with various surgical procedures, including nasal and sinus surgery.
Objectives
To report surgical experience using novel application of RADA16 hemostatic agent in facelift procedures.
Methods
Through exploring incorporation of RADA16 hemostatic agent into standard of care, 15 higher-risk facelift patients were treated intraoperatively between December 2020 and July 2021. Postoperative follow-up was on post-procedure day 1 and 3 and at approximately one week. During follow-up, potential complications were assessed subjectively, including hematoma, swelling, and bruising; postoperative observations recorded; and photographs taken.
Results
Among facelift patients receiving intraoperative RADA16 hemostatic agent there were no hematomas or protracted ecchymosis events. The only significant complication was one patient admitted for intravenous hydration due to post-operative nausea and vomiting. All patients had minimal bruising or a dramatic absence of bruising and experienced no hemorrhage or hematoma. Through surgical experience, technique for RADA16 hemostatic agent placement was optimized and procedural details are provided.
Conclusions
Intraoperative administration of topical RADA16 hemostatic agent appears to deter acute hematoma and hemorrhage formation and early experience suggests that RADA16 hemostatic agent may also attenuate post-operative bruising in facelift patients. These observations warrant further investigation in a larger randomized controlled study.
Level of Evidence: 4
Oxford University Press以上显示的是最相近的搜索结果。 查看全部搜索结果